Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

A phase II study of cabozantinib in patients (pts) with relapsed/refractory metastatic urothelial carcinoma (mUC)

Date

09 Oct 2016

Session

Poster display

Presenters

Rosa Nadal

Citation

Annals of Oncology (2016) 27 (6): 266-295. 10.1093/annonc/mdw373

Authors

R. Nadal1, H.L. Parnes1, D.C. Francis1, L.M. Cordes1, M. Berninger1, R. Costello1, L. Folio1, M. Linderberg1, L. Machado1, S.M. Steinberg1, J.J. Wright1, Y.M. Ning1, D.P. Bottaro1, W.L. Dahut2, A.B. Apolo3

Author affiliations

  • 1 Medical Oncology, National Cancer Institute, 20892 - Bethesda/US
  • 2 Genitourinary Malignancies Branch, National Cancer Institute, 20892 - Bethesda/US
  • 3 National Institutes Of Health, Genitourinary Malignancies Branch, Center for Cancer Research-National Cancer Institute, 20892 - Bethesda/US
More

Resources

Abstract 3756

Background

Hepatocyte growth factor (HGF) and its receptor (MET) are activated in UC. In translational studies, cabozantinib, a receptor tyrosine kinase inhibitor primarily targeting MET and VEGFR2, reversed HGF-driven UC cell growth and invasion.

Methods

In this phase II study, pts received cabozantinib 60 mg/day in 28-day cycles in 3 cohorts: 1) mUC, 2) bone-only mUC, and 3) metastatic rare bladder histology. Primary objective was overall response rate (ORR) by RECIST v1.1. In cohort 1, we also report on the tumor responses by site of metastases (mets). Secondary objectives were to assess the progression-free survival (PFS) and overall survival (OS) in all cohorts.

Results

Of 67 pts enrolled, 70% of male, median age: 63 (22–82), KPS 80% in 73% pts. Primary sites: 69% bladder, 25% upper tract, 6% both. No. prior therapies: 1/2/3/ ≥ 4 (range 1–6) in 34/39/16/9% of pts, respectively. Of 41 evaluable pts in cohort 1, there was 1 complete response (CR), 7 partial responses (PR) (ORR = 19.5%; 95% CI: 8.8–34.9%), 18 stable disease (SD), and 15 progressive disease (PD). Median progression-free survival (mPFS): 3.7 mos(95% CI: 2.3–6.5); 6-month PFS: 38.0%(95% CI: 23.3–52.6%). Median overall survival (mOS): 8.2 mos (95% CI: 5.2–10.3); 6-month OS: 65.1%(95% CI: 48.3–77.6%); 12-month OS: 25.7% (95% CI: 13.0–40.3%). ORR in cohort 1 was evaluated by site of mets in 63 target-lesions: 25.3%lung,/9.5%liver/6.3%adrenal/1.6%kidney/1.6% pancreatic/39.8% LN/15.9% ST. Lung mets had 25% PR/75% SD/0%PD. Treatment resulted in lung lesion cavitation, which could not be interpreted as CR (at best PR). Liver mets had 83.3%SD/16.7%PD. There was no ORR in liver/adrenal/kidney/pancreatic mets. LN mets had 8%CR/8%PR/72%SD/12%PD. ST mets had 90%SD/10%PD. Of 5 pts in cohort 2, 60% had improvement by NaF FDG/PET. mOS: 9.3 mos (95% CI: 3.6–12.5). Of 10 evaluable pts in cohort 3, there were 0%CR/PR/50%SD/50%PD. mPFS: 2.9 mos (95% CI: 1.8–3.7); mOS: 4.6 mos (95% CI: 2.6–8.0).

Conclusions

Cabozantinib has clinical activity in relapsed/refractory pts with mUC. Lung and LN mets had higher ORR. Lung lesion cavitation was frequently noted in responders. Further studies are underway to correlate responses with MET expression, immune subsets, CTCs, and cytokine/mutational profiles.

Clinical trial identification

NCT01688999

Legal entity responsible for the study

NCI/NHI

Funding

CTEP NIH

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings